Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on August 29, 2019. The filing discloses a material event regarding the departure of a senior officer and the subsequent appointment of a consulting arrangement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the compensation for a new consulting agreement:
- Consulting Fee: $15,000 per month.
- Term: Five months (October 1, 2019, through February 29, 2020).
- Service Requirement: At least 50 hours per month.
Material Changes
The primary material change is the resignation of Lisa Nolan, Ph.D., the Company's Chief Business Officer, effective September 30, 2019. Dr. Nolan is resigning to return to Ireland for career opportunities. Concurrently, the Company entered into a consulting agreement with Dr. Nolan to continue providing services in areas consistent with her prior role.
Outlook, Risks, and Management Commentary
Management has mitigated the immediate impact of the departure by retaining Dr. Nolan as a consultant. The agreement includes a provision allowing Rexahn to terminate the arrangement on or after December 31, 2019. No specific risks, contingencies, or unusual items beyond the personnel change are detailed in this filing.
Investor Verification Checklist
- Verify the effective date of the Chief Business Officer's resignation (September 30, 2019).
- Confirm the total potential cost of the consulting agreement ($75,000 over five months).
- Check for subsequent filings regarding the appointment of a permanent replacement for the Chief Business Officer role.
- Review the Company's latest 10-Q or 10-K for broader financial context, as this 8-K contains no operational financial data.